Getting the right treatment to the right patient at the right time is the backbone of market access. However, as with many things in life, the reality of achieving this goal is often far more complex than it is on paper.
Brands must navigate various moving parts to ensure that once a treatment gains approval, those who need it most have the knowledge and tools to access it. From global conflicts, supply chain disruptions, regulatory changes, and economic instability, many obstacles can impact this system, a challenge that pharma companies have faced time and time again.
The problem, as has been heavily illustrated through the ongoing abortion access debate in the US, is that disruptions to access can lead patients down a dark and dangerous path; a path to a black market of unregulated medications that threaten not only the safety of patients but the integrity of our industry.
So what is being done to move us closer to a future of harmonised market access? In this issue, we speak to Healthware’s Alberta Spreafico to learn more about the future of DTx in Europe, traverse the fractured landscape of menopause treatment and HRT access in the UK, and sit down with Takeda Pharmaceuticals’ Giles Platford, to discuss plasma shortages in the EU.
Plus, in our 12 questions with features, get to know PurpleLeaf’s Daniel Kohlstaedt and Beigene’s Gerwin Winter as they pull back the curtain to discuss key learnings and highlights from their professional and personal journeys.
For all this and more, read on.
Eloise McLennan – editor, Deep Dive
For the best page-viewing experience, make sure you have your browser at full-screen size. Use the left/right arrow buttons to scroll through the pages or click on the menu icon bottom centre to navigate. You can also share the articles on social media by clicking the icon bottom left at the base of the main navigation or at the end of each article.